SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 4, 2021--
Cortexyme, Inc. (Nasdaq: CRTX) announced that it will participate at the 14th Clinical Trials on Alzheimer's Disease Conference (CTAD 2021) as a part of the meeting’s Late-Breaking Readout Roundtable program on Thursday, November 11, 2021, at 11:35 a.m. Eastern Time in Boston, Massachusetts. During the company’s 30-minute presentation, Cortexyme’s chief medical officer Michael Detke, MD, PhD, and GAIN Trial lead investigator Marwan Sabbagh, MD, FAAN, will provide additional GAIN Trial top-line results and analysis.
CTAD 2021 Late-Breaking Readout Roundtable Details
Title: Top-line Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease.
Presenters: Michael Detke, MD, PhD, Cortexyme’s chief medical officer and GAIN Trial lead investigator Marwan Sabbagh, MD, FAAN, Professor of Neurology at the Alzheimer's and Memory Disorders Division of the Barrow Neurological Institute at Dignity Health/St. Joseph's Hospital and Medical Center.
Authors: Michael Detke1, Marwan Sabbagh2, Mark Ryder3, Joanna Bolger1, Dave Hennings1, Vladimir Skljarevski1, Shirin Kapur1, Debasish Raha1, Florian Ermini1, Mai Nguyen1, Ursula Haditsch1, Kim Perry4, Kelly Ritch5, Suzanne Hendrix6, Sam Dickson6, Hatice Hasturk7, Sarah Horine1, Craig Mallinckrodt1, Leslie Holsinger1, Casey Lynch1, and Stephen Dominy1.
Access: Cortexyme’s CTAD 2021 presentation will be accessible on Thursday, November 11, 2021, beginning at 11:35 a.m. Eastern Time via the company’s Investor Relations website at ir.cortexyme.com, in addition to being accessible to CTAD registered meeting attendees in-person and on its virtual platform.
1Cortexyme - South San Francisco, CA (USA), 2Barrow Neurological Institute, Dignity Health/St. Joseph’s Hospital and Medical Center - Phoenix, AZ (USA), 3UCSF - San Francisco, CA (USA), 4Innovative Analytics - Portage, MI (USA), 5Datafy Clinical R&D - Portage, MI (USA), 6Pentara Corporation - Millcreek, UT (USA), 7Forsyth Institute - Cambridge, MA (USA)
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Cortexyme’s lead program targets a specific, infectious pathogen called P. gingivalis found in the brain of Alzheimer’s patients and other organs and tied to degeneration and inflammation in humans and animal models. The company’s causation evidence for Alzheimer’s disease and the mechanism of its novel therapeutic has been independently replicated and confirmed by multiple laboratories around the world, as well as published in peer-reviewed scientific journals. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211104005314/en/
Vice President, Corporate Communications & Investor Relations
Source: Cortexyme, Inc.